Skip to Content
Merck
HomeWebinarsHigh Concentration Ultrafiltration: Formulation Challenges & Mitigation Strategies

High Concentration Ultrafiltration: Formulation Challenges & Mitigation Strategies



WEBINAR

Tangential flow filtration (TFF) using ultrafiltration membranes is commonly used for the final formulation and concentration of monoclonal antibodies. Injection of liquid formulations is often the preferred method of administration for these therapeutics. In cases where high dosages are required, manufacturers frequently target high concentration liquid formulations which can result in high viscosity solutions. Highly concentrated protein solutions have challenges associated with formulation. This webinar presents the formulation challenges that are associated with plausible risk mitigation strategies to overcome such formulation challenges.

In this webinar you will learn about:

  • High concentration UF-DF optimization
  • Scaling up the UF-DF step
  • Models to explain buffer offsets
  • Process Development to mitigate buffer offsets

Speaker

Subhasis Banerjee, Ph.D.

Subhasis Banerjee, Ph.D.

Merck

Principal Process Consultant

Subhasis Banerjee is the Principal Process Consultant in Asia Pacific for Merck Life Sciences based out of Bangalore, India. Subhasis supports technical consultation for downstream processing for the APAC region. Previously he was heading the Manufacturing Sciences and Technology group; team of Scientists and Engineers for Singapore, South East Asia and Oceania supporting in optimizing downstream unit operations and providing scale up solutions to biological manufacturers. He is a Ph.D. in Biochemistry with a post-doctoral experience from The Ohio State University, Columbus, Ohio, USA. Dr. Banerjee has several publications in international peer reviewed journals and presentations in several national and International Conferences.